Literature DB >> 7907678

Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

D Ford1, D F Easton, D T Bishop, S A Narod, D E Goldgar.   

Abstract

Germline mutations in a gene on chromosome 17q known as BRCA1 are responsible for a large proportion of inherited predispositions to breast and ovarian cancer. In 33 families with evidence of linkage to BRCA1, we estimated the risks of breast and ovarian cancer from the occurrence of second cancers in individuals with breast cancer, and examined the risks of other cancers in BRCA1 carriers. 26 contralateral primary breast cancers occurring more than 3 years after a first breast cancer were observed before age 70, giving an estimated cumulative risk of breast cancer in gene carriers of 87% by age 70.23 primary ovarian cancers occurred in women with a previous breast cancer, resulting in an estimated cumulative risk of ovarian cancer of 44% by age 70.87 cancers other than breast or ovarian cancer were observed in individuals with breast or ovarian cancer and their first-degree relatives compared with 69.3 expected, based on national incidence rates. Significant excesses were observed for colon cancer (estimated relative risk [RR] to gene carriers 4.11 [95% CI 2.36-7.15]) and prostate cancer (3.33 [1.78-6.20]). No significant excesses (or deficits) were noted for cancers of other sites. Our study provides estimates of breast and ovarian cancer risks which are useful for counselling BRCA1-mutation carriers. It also shows that carriers are at increased risk of colon and prostate cancer, which may be of clinical significance in certain families if the risks are associated with specific mutations.

Entities:  

Mesh:

Year:  1994        PMID: 7907678     DOI: 10.1016/s0140-6736(94)91578-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  413 in total

1.  A highly accurate, low cost test for BRCA1 mutations.

Authors:  N J van Orsouw; R K Dhanda; Y Elhaji; S A Narod; F P Li; C Eng; J Vijg
Journal:  J Med Genet       Date:  1999-10       Impact factor: 6.318

2.  Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group.

Authors:  L N Lodder; P G Frets; R W Trijsburg; E J Meijers-Heijboer; J G Klijn; H J Duivenvoorden; A Tibben; A Wagner; C A van der Meer; P Devilee; C J Cornelisse; M F Niermeijer
Journal:  J Med Genet       Date:  1999-12       Impact factor: 6.318

Review 3.  The complexities of predictive genetic testing.

Authors:  J P Evans; C Skrzynia; W Burke
Journal:  BMJ       Date:  2001-04-28

4.  Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG).

Authors:  D M Eccles; D G Evans; J Mackay
Journal:  J Med Genet       Date:  2000-03       Impact factor: 6.318

5.  BRCA1 and BRCA2 testing: weighing the demand against the benefits.

Authors:  P Devilee
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

Review 6.  Forth nightly review: hereditary ovarian carcinoma.

Authors:  L Kasprzak; W D Foulkes; A N Shelling
Journal:  BMJ       Date:  1999-03-20

Review 7.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

8.  Developing strategies for reducing cancer disparities via cross-institutional collaboration: outreach efforts for the partnership between the Ponce School of Medicine and the Moffitt Cancer Center.

Authors:  Clement K Gwede; Eida Castro; Thomas H Brandon; Jessica McIntyre; Cathy D Meade; Teresita Munoz-Antonia; Vani N Simmons; Susan T Vadaparampil; Julio Jimenez; Gwendolyn P Quinn
Journal:  Health Promot Pract       Date:  2011-12-12

9.  High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects.

Authors:  G Goelen; E Teugels; M Bonduelle; B Neyns; J De Grève
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

10.  Effect of pentoxifylline on tumor suppressor and proto-oncogene apoptosis in sperm.

Authors:  David T Maxwell; John D Jacobson; Alan King; Philip J Chan
Journal:  J Assist Reprod Genet       Date:  2002-06       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.